Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DARVOCET A500 vs VICOPROFEN
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Combination analgesic: acetaminophen inhibits cyclooxygenase (COX) and modulates endocannabinoid system; propoxyphene is a mu-opioid receptor agonist.
Hydrocodone is a mu-opioid receptor agonist that activates G-protein coupled opioid receptors, leading to analgesia; ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis.
Mild to moderate pain
Short-term (generally <10 days) management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate
One tablet (500 mg acetaminophen, 100 mg propoxyphene napsylate) orally every 4 hours as needed for pain; maximum 6 tablets per day.
1 tablet (hydrocodone 5 mg / ibuprofen 200 mg) orally every 4 to 6 hours as needed for pain; maximum 5 tablets per day.
Propoxyphene: 6-12 hours (terminal, prolonged in elderly, hepatic impairment, or overdose). Acetaminophen: 2-3 hours (terminal, prolonged in hepatic impairment or overdose).
Hydrocodone: 3.8-4.5 hours (immediate-release); clinical context: analgesic duration correlates with half-life, but may be prolonged in renal/hepatic impairment. Ibuprofen: 2-4 hours (immediate-release); clinical context: anti-inflammatory effect may outlast plasma half-life due to tissue distribution.
Contraindicated in severe renal impairment (Cr Cl <30 m L/min). For GFR 30-50 m L/min: reduce dose to 1 tablet every 6 hours. Monitor for propoxyphene accumulation.
Avoid use if Cr Cl <30 m L/min; for Cr Cl 30-59 m L/min, reduce dose frequency and avoid prolonged use due to ibuprofen component.
Propoxyphene is associated with fatal respiratory depression, abuse potential, and risk of overdose; contraindicated in patients with suicidal ideation or addiction.
First trimester: Propoxyphene crosses placenta, limited data; possible association with neural tube defects. Second trimester: Avoid; risk of fetal respiratory depression. Third trimester: Avoid; neonatal withdrawal syndrome (tremors, hypertonia) and respiratory depression at delivery.
First trimester: NSAIDs associated with increased risk of miscarriage and cardiac defects. Second trimester: Potential for oligohydramnios and fetal renal dysfunction. Third trimester: Risk of premature closure of ductus arteriosus, oligohydramnios, and neonatal renal impairment.
Darvocet A500 contains propoxyphene and acetaminophen. Propoxyphene is a weak mu-opioid agonist with high interindividual variability in metabolism. Avoid in patients with creatinine clearance <30 m L/min due to accumulation of norpropoxyphene, which can cause cardiac toxicity (QT prolongation, risk of fatal arrhythmias). Do not exceed 600 mg propoxyphene base (or equivalent) per day. Monitor liver function due to acetaminophen, especially in patients with hepatic impairment or chronic alcohol use. Use with caution in elderly due to increased fall risk and respiratory depression.
Vicoprofen is a fixed-dose combination of hydrocodone bitartrate (an opioid agonist) and ibuprofen (an NSAID). It is indicated for short-term (generally <10 days) management of acute pain severe enough to require an opioid and for which alternative treatments are inadequate. The maximum daily dose is 5 tablets of 7.5 mg hydrocodone/200 mg ibuprofen, not to exceed 5 days due to ibuprofen-associated GI and renal risks. Monitor for respiratory depression, especially in opioid-naïve patients, and assess for signs of NSAID-related bleeding, renal impairment, or cardiovascular events. Abrupt discontinuation may precipitate withdrawal symptoms. Avoid co-prescription with other CNS depressants or NSAIDs.
No interactions on record
No interactions on record
DARVOCET A500 and VICOPROFEN are distinct pharmacological agents. DARVOCET A500 belongs to the Opioid Analgesic Combination class and is primarily used for Mild to moderate pain. VICOPROFEN belongs to the Opioid Analgesic Combination class and is primarily used for Short-term (generally <10 days) management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Their specific mechanisms of action, pharmacokinetic characteristics, and side effects differ.
The maternal-fetal safety profiles of these drugs differ. DARVOCET A500 carries a safety status of Category C, whereas VICOPROFEN safety is classified as Category C. Consult a board-certified physician or healthcare specialist to establish an accurate, individualized pregnancy risk assessment before starting either therapy.
Propoxyphene: hepatic via CYP3A4 and CYP2D6; active metabolite norpropoxyphene. Acetaminophen: hepatic via conjugation (glucuronidation, sulfation) and CYP2E1.
Hydrocodone is metabolized via CYP3A4 and CYP2D6; ibuprofen is primarily metabolized by CYP2C9.
Propoxyphene: ~20-25% renal as unchanged drug, ~35% as norpropoxyphene, ~20% biliary/fecal. Acetaminophen: ~2-4% renal unchanged, ~85% as glucuronide and sulfate conjugates, ~5% as cysteine and mercapturate conjugates.
Hydrocodone: primarily renal (26% as unchanged drug and metabolites, including norhydrocodone, hydromorphone, and conjugates); less than 5% fecal. Ibuprofen: renal (50-60% as unchanged drug and metabolites, mainly conjugated with glucuronic acid; <10% unchanged); biliary/fecal (minor).
Propoxyphene: ~78% bound to albumin. Acetaminophen: 10-25% bound (minimal).
Hydrocodone: approximately 20-30% bound to plasma proteins (albumin). Ibuprofen: >99% bound to albumin.
Propoxyphene: 16 L/kg (extensive tissue distribution). Acetaminophen: 0.9 L/kg.
Hydrocodone: 3.3 L/kg (large Vd indicates extensive tissue distribution). Ibuprofen: 0.1-0.3 L/kg (low Vd reflects high protein binding and limited extravascular distribution).
Propoxyphene: 30-70% (first-pass metabolism). Acetaminophen: ~88% (oral).
Oral: hydrocodone bioavailability 60-80% (due to first-pass metabolism); ibuprofen bioavailability 80-100% (rapid absorption).
Avoid use in Child-Pugh class C (severe hepatic impairment). In Child-Pugh class A or B: use with caution, reduce dose by 50% (e.g., 1 tablet every 6-8 hours), and avoid chronic use due to acetaminophen toxicity risk.
Contraindicated in severe hepatic impairment (Child-Pugh class C); for moderate impairment (Child-Pugh class B), use with caution and consider dose reduction.
Not recommended for pediatric use due to safety concerns (propoxyphene associated with respiratory depression in children). For adolescents >12 years: 1 tablet every 4 hours as needed; maximum 6 tablets/day.
Not recommended for use in pediatric patients (safety and efficacy not established).
Start at 1 tablet every 6-8 hours; avoid exceeding 4 tablets/day. Monitor for CNS depression, constipation, and falls. Consider decreased hepatic/renal function and increased sensitivity.
Use lowest effective dose for shortest duration; increased risk of GI bleeding and renal impairment; monitor renal function and avoid prolonged use.
Risk of addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion (especially in children) can be fatal; neonatal opioid withdrawal syndrome with prolonged use during pregnancy; risks from concomitant use with benzodiazepines or other CNS depressants (additive effects); hepatotoxicity from ibuprofen (NSAID).
Risk of respiratory depression, abuse and dependence, cardiac toxicity (QT prolongation, arrhythmias), acetaminophen hepatotoxicity, increased seizure risk in patients with CNS depression, interaction with CNS depressants.
Addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; risks with benzodiazepines or other CNS depressants; hepatotoxicity; cardiovascular thrombotic events; gastrointestinal bleeding; renal toxicity; hypertension; anaphylactoid reactions; serious skin reactions; use in patients with renal or hepatic impairment; pregnancy; lactation.
Hypersensitivity to propoxyphene or acetaminophen, significant respiratory depression, acute or severe bronchial asthma, paralytic ileus, known CYP2D6 ultrarapid metabolizers, concomitant use of MAOIs or within 14 days, suicidal patients, addiction-prone individuals.
Hypersensitivity to hydrocodone, ibuprofen, or any component of the product; significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment; known or suspected gastrointestinal obstruction, including paralytic ileus; history of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs; in the setting of coronary artery bypass graft (CABG) surgery.
Take with food to reduce gastrointestinal upset. Avoid grapefruit juice as it may increase propoxyphene absorption. Avoid alcohol entirely due to increased hepatotoxicity and CNS depression. High-fat meals may delay absorption of propoxyphene, but no specific restrictions.
Avoid alcohol while taking Vicoprofen. Take with food or milk to reduce GI upset. Grapefruit juice may increase hydrocodone levels; avoid consuming large amounts. There are no other significant food interactions.
Propoxyphene and acetaminophen are excreted into breast milk. M/P ratio for propoxyphene ~0.5-1.0; low relative infant dose (~2% maternal). Acetaminophen M/P ~0.9. Use caution; monitor infant for sedation, poor feeding. AAP considers compatible.
Excreted in breast milk in low amounts. M/P ratio for hydrocodone is approximately 2.5 for total opioids; ibuprofen M/P ratio is <1. Use with caution; monitor infant for sedation, respiratory depression, and poor feeding.
Pharmacokinetic changes: Increased renal clearance and volume of distribution may reduce propoxyphene levels; no established dose adjustment guidelines. Acetaminophen levels unchanged. Use lowest effective dose for shortest duration.
Avoid use during pregnancy, especially in third trimester. If necessary, use lowest effective dose for shortest duration. No specific dose adjustment pharmacokinetics established; consider that volume of distribution and clearance may change, but no formal guidelines exist.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Do not drink alcohol while taking this medication; it increases risk of liver damage and sedation.,Avoid driving or operating heavy machinery until you know how this drug affects you.,Do not take other medications containing acetaminophen to avoid exceeding the maximum daily dose (3000 mg).,Contact your doctor immediately if you experience irregular heartbeat, fainting, or severe dizziness.,Store at room temperature, away from moisture and heat, and out of reach of children.,Do not share this medication with others; it can cause serious harm or death.,If you miss a dose, skip it and resume your regular schedule; do not double the dose.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Do not take with other products containing acetaminophen, NSAIDs (e.g., ibuprofen, naproxen), or opioids.,Avoid alcohol while taking this medication as it increases risk of liver damage, stomach bleeding, and respiratory depression.,May cause drowsiness or dizziness; do not drive or operate machinery until you know how this medication affects you.,Seek emergency medical attention if you experience difficulty breathing, chest pain, severe drowsiness, or signs of allergic reaction.,If you miss a dose, take it as soon as you remember. If it is near time for the next dose, skip the missed dose. Do not double the dose.,Do not stop taking abruptly without talking to your doctor; a gradual dose reduction may be needed to avoid withdrawal symptoms.,Store at room temperature away from moisture and heat. Keep out of reach of children.,Report any new or worsening pain, signs of stomach bleeding (vomit that looks like coffee grounds, black/tarry stools), or symptoms of kidney problems (e.g., change in urine output, swelling in legs/ankles).,This medication may cause constipation; increase fluid and fiber intake, and consider a stool softener if needed.